GJA1 and cardiac rhythm disease: Previous clinical trials have indicated the importance of connexin-43 expression for cardiac cell therapy, as observed by the MAYOHEART cell randomized trial, in which connexin-43 negative skeletal muscle myocytes were applied for stem cell therapy, but ended in one death and six patients experiencing treatment related to cardiac arrhythmias 25.